ArticleClinical and translational radiation oncology2027
CyberKnife SBRT plus lenvatinib and tislelizumab versus doublet systemic therapy for hepatocellular carcinoma with macrovascular invasion: A real-world IPTW-adjusted study.
Sujing Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.